Cargando…

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauko, Adam, Kotecha, Rupesh, Barnett, Addison, Li, Hong, Tatineni, Vineeth, Ali, Assad, Patil, Pradnya, Mohammadi, Alireza M., Chao, Samuel T., Murphy, Erin S., Angelov, Lilyana, Suh, John H., Barnett, Gene H., Pennell, Nathan A., Ahluwalia, Manmeet S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438061/ https://www.ncbi.nlm.nih.gov/pubmed/34518623 http://dx.doi.org/10.1038/s41598-021-97566-z

Ejemplares similares

Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-16. EFFICACY OF UPFRONT IMMUNE CHECKPOINT INHIBITORS IN LUNG CANCER BRAIN METASTASIS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-02. IMPACT OF SYSTEMIC THERAPY IN MELANOMA BRAIN METASTASIS
por: Sagar, Soumya, et al.
Publicado: (2019)

THER-14. INFLUENCE OF CLINICAL PARAMETERS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (NSCLCBM)
por: Lauko, Adam, et al.
Publicado: (2019)

RADI-35. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS
por: Kotecha, Rupesh, et al.
Publicado: (2019)

RADI-25. REPEAT STEREOTACTIC RADIOSURGERY FOR RECURRENT BRAIN METASTASES
por: Krivosheya, Daria, et al.
Publicado: (2019)

First follow‐up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases
por: Sharma, Mayur, et al.
Publicado: (2017)

TRLS-05. EARLY RESULTS FROM A PROSPECTIVE PHASE I/II DOSE ESCALATION STUDY OF NEOADJUVANT RADIOSURGERY FOR BRAIN METASTASES
por: Murphy, Erin, et al.
Publicado: (2019)

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Medical management of brain metastases
por: Lauko, Adam, et al.
Publicado: (2020)

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases
por: Tonse, Raees, et al.
Publicado: (2021)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Editorial: Effects of radiation therapies on brain metastases
por: Kotecha, Rupesh, et al.
Publicado: (2023)

An Excellent Clinical Outcome with Stereotactic Radiosurgery in a Geriatric Patient with Multiple and Recurrent Brain Metastases
por: Thapa, Bicky, et al.
Publicado: (2017)

Recent advances in managing brain metastasis
por: Kotecha, Rupesh, et al.
Publicado: (2018)

Evaluating the intracranial activity of adagrasib
por: Kotecha, Rupesh, et al.
Publicado: (2023)

Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States
por: Tonse, Raees, et al.
Publicado: (2021)

Targeted therapy of brain metastases: latest evidence and clinical implications
por: Di Lorenzo, Rodica, et al.
Publicado: (2017)

Update on the Management of Brain Metastasis
por: Singh, Karanvir, et al.
Publicado: (2022)

Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases
por: Kotecha, Rupesh, et al.
Publicado: (2022)

Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife(®) Icon™ Stereotactic Radiosurgery for Brain Metastases
por: Kutuk, Tugce, et al.
Publicado: (2022)

Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas
por: La Rosa, Alonso, et al.
Publicado: (2023)

Laser interstitial thermal therapy for brain metastases
por: Srinivasan, Ethan S, et al.
Publicado: (2021)

DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
por: Ozair, Ahmad, et al.
Publicado: (2023)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Optimal management of atypical hemolytic uremic disease: challenges and solutions
por: Raina, Rupesh, et al.
Publicado: (2019)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins
por: Grabowski, Matthew M., et al.
Publicado: (2023)

TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh, et al.
Publicado: (2019)

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh P, et al.
Publicado: (2020)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

Prediction of recurrent glioblastoma after laser interstitial thermal therapy: The role of diffusion imaging
por: Mahammedi, Abdelkader, et al.
Publicado: (2019)

OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
por: Tonse, Raees, et al.
Publicado: (2021)

Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis
por: Tonse, Raees, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bpc1m0hsb9qocfh7ssin91jt89